How do you treat elderly or frail patients with metastatic RCC?  

This is an important question as we enter the era of combination therapies in all risk categories, thus exposing patients to more side effects. I prefer to start with a single agent Checkpoint inhibitor with plans to escalate to combinations if there is disease progression. The OMNIVORE study and ot...